Home › Companies › PMV PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and PMV PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024
Explore PMV PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are PMV PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Kirsten Flowers | 35,683,498 | -- | -- | 656,260 | 7,211,791 | Majority: yes |
| Elect Director: Carol Gallagher, Pharm.D. | 27,082,825 | -- | -- | 9,256,933 | 7,211,791 | Majority: yes |
| Proposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as descr | 34,452,101 | 1,079,423 | 808,234 | -- | 7,211,791 | Majority: yes |
| Consistent with the recommendation of the Company's Board of Directors and based on the Company's stockholders' approval at the Company's 2022 annual meeting of stockholders, held on June 2, 2022, the Company conducts non-binding advisory v | 43,460,392 | 90,902 | 255 | -- | -- | Majority: yes |
Source: PMV PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.
Each item below shows how the 111 asset managers that disclosed a PMV PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of PMV PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
PMV PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding advisory basis, the compensation paid to its named executi”): 34,452,101 for, 1,079,423 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,443,488 outstanding shares: 67% for, 2% against (69% of the company cast a for/against vote).
The 110 asset managers below cast 98% of the shares they voted on this item FOR (29,662,269 for, 697,943 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 6,475,291 | 0 | 0 | 0 | For |
| Vanguard | 2,457,358 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 2,419,625 | 0 | 0 | 0 | For |
| BlackRock | 2,011,204 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 1,275,462 | 0 | 0 | 0 | For |
| Citadel | 1,240,158 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 903,137 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 868,385 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 860,910 | 0 | 0 | 0 | For |
| Fidelity | 853,469 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 820,500 | 0 | 0 | 0 | For |
| State Street | 762,877 | 57 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 758,094 | 0 | 0 | 0 | For |
| DE Shaw | 756,917 | 0 | 0 | 0 | For |
| Goldman Sachs | 656,652 | 0 | 0 | 0 | For |
| Two Sigma | 644,032 | 0 | 0 | 0 | For |
| SEI | 600,646 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 566,879 | 0 | 0 | 0 | For |
| Charles Schwab | 532,180 | 0 | 0 | 0 | For |
| Opaleye Management Inc. | 450,000 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 328,640 | 0 | 0 | 0 | For |
| Northern Trust | 233,500 | 0 | 0 | 0 | For |
| Point72 | 214,841 | 0 | 0 | 0 | For |
Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.
Combines 4 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
PMV PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carol Gallagher, Pharm.D.”): 27,082,825 for, 9,256,933 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,443,488 outstanding shares: 52.6% for, 18% withheld (71% of the company cast a for/withheld vote).
The 45 asset managers below cast 100% of the shares they voted on this item FOR (6,324,882 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 845,206 | 0 | 6,800 | 0 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 364,929 | 0 | Abstain |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 329,949 | 0 | Abstain |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 71,804 | 0 | 50,500 | 0 | For |
| Dimensional | 0 | 0 | 103,261 | 0 | Abstain |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 1,483 | 0 | 82,944 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 55,500 | 0 | Abstain |
| American Century | 0 | 0 | 50,087 | 0 | Abstain |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,400 | 0 | 6,343 | 0 | For |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 20,217 | 0 | Abstain |
| GuideStone | 0 | 0 | 17,857 | 0 | Abstain |
| AQR | 0 | 0 | 16,577 | 0 | Abstain |
| Jackson National | 0 | 0 | 16,475 | 0 | Abstain |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
PMV PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kirsten Flowers”): 35,683,498 for, 656,260 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,443,488 outstanding shares: 69% for, 1% withheld (71% of the company cast a for/withheld vote).
The 45 asset managers below cast 100% of the shares they voted on this item FOR (7,333,166 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 852,006 | 0 | 0 | 0 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 364,929 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 71,804 | 0 | 50,500 | 0 | For |
| Dimensional | 0 | 0 | 103,261 | 0 | Abstain |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 84,427 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 55,500 | 0 | 0 | 0 | For |
| American Century | 50,087 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,400 | 0 | 6,343 | 0 | For |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,217 | 0 | 0 | 0 | For |
| GuideStone | 17,857 | 0 | 0 | 0 | For |
| AQR | 16,577 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 16,475 | 0 | Abstain |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 45 asset managers below cast 100% of the shares they voted on this item FOR (7,514,884 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 852,006 | 0 | 0 | 0 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 364,929 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 122,304 | 0 | 0 | 0 | For |
| Dimensional | 103,261 | 0 | 0 | 0 | For |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 84,427 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 55,500 | 0 | 0 | 0 | For |
| American Century | 50,087 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 38,743 | 0 | 0 | 0 | For |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,217 | 0 | 0 | 0 | For |
| GuideStone | 17,857 | 0 | 0 | 0 | For |
| AQR | 16,577 | 0 | 0 | 0 | For |
| Jackson National | 16,475 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Ranked by the number of PMV PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 51,443,488 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 12.59% |
| 2 | Vanguard | 4.78% |
| 3 | ArrowMark Colorado Holdings LLC | 4.70% |
| 4 | BlackRock | 3.91% |
| 5 | PFM Health Sciences, LP | 2.48% |
| 6 | Citadel | 2.41% |
| 7 | MERIDIAN FUND INC | 2.35% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.76% |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 1.69% |
| 10 | ALKEON CAPITAL MANAGEMENT LLC | 1.67% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with OrbiMed Advisors | 12.76% | DEF14A |
| Entities affiliated with BlackRock, Inc. | 6.28% | DEF14A |
| ArrowMark Colorado Holdings, LLC | 5.28% | DEF14A |
| Vanguard Group | 4.20% | 13F |
| David H. Mack, Ph.D. | 4.18% | DEF14A |
| BlackRock | 2.15% | 13F |
| Geode Capital | 1.76% | 13F |
| State Street | 1.53% | 13F |
| D.E. Shaw | 1.40% | 13F |
| Millennium Management | 1.27% | 13F |
Percentages above are of 51,443,488 shares outstanding, as reported by PMV PHARMACEUTICALS INC. on its Form 10-Q dated 2024-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PMV PHARMACEUTICALS INC.’s 10-Q dated 2024-05-08. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At PMV PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 111 asset managers reported how they voted in their SEC Form N-PX filings, covering 611 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: PMV PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.
PMV PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).